Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group

Graaf, Marlies de; Raphaël, Martine F.; Breugem, Corstiaan C.; Knol, Mirjam J.; Bruijnzeel-Koomen, Carla A.F.M.; Kon, Moshe; Breur, Johannes M.P.J.; Pasmans, Suzanne G.M.A.

doi:10.1016/j.bjps.2013.07.035

Cited by 62 publications

(83 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the hydrophilic and more selective β-blocker atenolol is a promising alternative, its efficacy, side effects and adverse events spectrum have not been studied as extensively yet. [27][28][29][51][52][53] Topical β-blocker treatment possibly has less systemic adverse effects but it seems to be effective only in superficial IH. [31] ACE-inhibition seems to be a good alternative by its action mechanism, although literature is very limited and renal adverse effects at young age can be harmful.…”

Section: Discussionmentioning

confidence: 99%

“…[27] Atenolol is a hydrophilic β-blocker, acting on β-1 receptors with a proven efficacy in the treatment of IH. [28,29] Another explanation for the effect of atenolol could be the limited β-2-blocking potential of atenolol. [30] In the studies used in this overview, the reported side effects and adverse events noted were hypotension, sleep disturbance, constipation, diarrhea, cold extremities and vomiting.…”

Section: Atenololmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Raphaël

Breur

Vlasveld

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: While options for treatment strategies for infantile hemangiomas (IH) are numerous, evidence-based information about agents, optimal dosage, adverse effects, treatment modality, pretreatment and treatment strategies remain limited. Areas covered: To evaluate side effects and adverse events of medical treatment in children with infantile hemangioma, a comprehensive review of the literature was performed to provide information for daily practice. In total 254 studies were retrieved from medical databases and comprised 10,022 patients divided into 5 different treatment groups. Information about working mechanism, side effects and adverse events of therapies used as a single agent for IH are discussed and evaluated according to information from pharmacotherapeutic databases. Randomized controlled trials have only scarcely been performed for the many therapeutic options reported for IH. Short-and long-term side effects and adverse events, have not been systematically studied. Subsequently information about the medical treatment options and pharmacotheraputic databases for therapy in children with IH are incomplete. Expert opinion: From the many therapeutic options, propranolol is the first-line approach for IH, predominantly based on clinical observation, efficacy and tolerability in the short-term. The unsolved ravels of possible short and long-term adverse events of propranolol used during early developmental stages of children need thorough review.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Atenololmentioning

confidence: 99%

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Raphaël

Breur

Vlasveld

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…L'acebutolol [12] et l'aténolol [13] sont moins lipophile que le propranolol, ils ne passent pas, ou très peu la barrière hémato-méningée et donneraient moins de troubles du sommeil. Par ailleurs, en raison de leur cardiosélectivité, ils ont été proposés chez les nourrissons prédisposés à l'asthme, cependant, leur effet thérapeutique semble quand même moindre, et à des doses élevées la cardiosélectivité est relative.…”

Section: D'autres Bêtabloquants Sont-ils Efficaces ?unclassified

Traitement par propranolol des hémangiomes infantiles

Léauté‐Labrèze

2015

Archives de Pédiatrie

View full text Add to dashboard Cite

“…10 Another resulted in 90% clinical involution for atenolol and 100% clinical involution for propranolol. 11 Although these studies were limited in sample size and varied among clinical presentation, the results illustrated clinically relevant outcomes for atenolol. The comparison of the 2 trials can be seen in the Table. Two possible mechanisms exist regarding the adverse temperature effect seen in propranolol.…”

Section: Discussionmentioning

confidence: 99%

Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma

Burkey¹,

Jacobs²,

Aziz³

2017

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

Infantile hemangiomas are prevalent in the first few months of life and can be associated with risks of scarring, blindness, ulcerations, and airway obstruction depending on the location of lesions. Options for therapy include surgery, laser therapy, or medications. Propranolol is the only US Food and Drug Administration-approved medication option. Propranolol is a nonselective beta-blocker that crosses the blood-brain barrier because of its high lipophilicity, which increases the likelihood of central nervous system effects. In this case, a preterm infant developed infantile hemangiomas on the left forearm, left trunk, left buttock, and nasal tip. The patient was treated with propranolol and concurrently required placement into a heated incubator and was subsequently unable to wean from the incubator. Upon discontinuation of propranolol, temperature instability resolved. Atenolol, a cardioselective beta-blocker that does not cross the blood-brain barrier, was then initiated for the infantile hemangiomas and displayed no adverse effect on the thermoregulation of the infant.

show abstract

Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group

Cited by 62 publications

References 40 publications

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Traitement par propranolol des hémangiomes infantiles

Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma

Contact Info

Product

Resources

About